Table 2 Analysis of features among BRCA1-, BRCA2- and non-BRCA1/2-associated cancers and in unselected cancers
N (frequency, %) | P | ||||
|---|---|---|---|---|---|
Feature | BRCA1 | BRCA2 | Non-BRCA1/2 | Unselected | |
Histology | |||||
Ca ductale | 37 (72.5) | 37 (62.7) | 102 (67.1) | 561 (65.1) | |
Ca lobulare | 8 (15.7) | 17 (28.8) | 30 (19.7) | 219 (25.4) | |
Ca medullare | 5 (9.8) | - | 3 (2.0) | 20 (2.3) | 0.013*, 0.001** |
Others | 1 (2.0) | 5 (8.5) | 17 (11.2) | 62 (7.2) | |
Grade | |||||
I | 3 (6.1) | 12 (23.1) | 46 (32.4) | 152 (23.3) | |
II | 11 (22.4) | 26 (50.1) | 66 (46.5) | 289 (44.4) | |
III | 35 (71.4) | 14 (26.9) | 30 (21.1) | 210 (32.3) | |
I–II | 14 (28.6) | 38 (73.1) | 112 (78.9) | 441 (67.7) | ≤ 0.0005*, <0.0005**, 0.009**** |
Immunohistochemistry | |||||
ER- | 28 (66.7) | 17 (32.1) | 40 (27.0) | 167 (19.4) | ≤ 0.0005*, <0.0005**, 0.026***, 0.035**** |
ER+ | 14 (33.3) | 36 (67.9) | 108 (73.0) | 692 (80.6) | |
PgR- | 37 (84.1) | 28 (51.9) | 67 (45.3) | 312 (36.2) | ≤ 0.0005*, <0.0005**, 0.021***, 0.036**** |
PgR+ | 7 (15.9) | 26 (48.1) | 81 (54.7) | 549 (63.8) | |
p53- | 27 (62.8) | 42 (82.4) | 118 (78.7) | 628 (74.0) | 0.034*, <0.0005** |
p53+ | 16 (37.2) | 9 (17.6) | 32 (21.3) | 221 (26.0) | |
erbB2- | 35 (81,4) | 45 (84,9) | 109 (82,6) | NA | |
erbB2+ | 8 (18,6) | 8 (15,1) | 23 (17,4) | NA | |